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Arsenic is classified as a carcinogen by the
U.S. Environmental Protection Agency (U.S.
EPA) (Smith et al. 1992). Exposure to arsenic
in drinking water is associated with increased
risk of skin, kidney, lung, and bladder can-
cers. Chronic effects of arsenic in the water
supply include skin hyperpigmentation and
keratoses of the hands and feet that frequently
progress to skin cancers. In about 10% of
these cases, exposure is associated with a very
high incidence of lung, bladder, and other
cancers. According to the National Resources
Defense Council (NRDC), millions of
Americans are consuming tap water every day
that poses unacceptable cancer risks (NRDC
2001). Over 56 million Americans in the 25
reporting states consumed water from systems
containing arsenic at levels presenting a
potentially fatal cancer risk. In 1976 the U.S.
EPA set the maximum contamination level
(MCL) for arsenic at 50 µg/L. The National
Research Council, the operating arm of the
U.S. National Academy of Sciences, has rec-
ommended an MCL of 10 µg/L (U.S. EPA
2001), which will be put in place in the
near future.
Arsenic enters the water supply primarily
from geochemical sources (USGS 1998a). In
Michigan, arsenic leaches into water from
the Marshall Sandstone and Coldwater Shale
(Detroit Free Press 1999; USGS 1998b). In
regions of Oakland County the concentra-
tion of arsenic in water supplies greatly
exceeds the current U.S. EPA MCL of 50
µg/L (Detroit Free Press 1999). Based on
geology and limited sampling, 20–30% of
water supply wells in Michigan have concen-
trations exceeding 10 µg/L. 
Although in general arsenic enters the bio-
sphere by leaching from geologic formations,
anthropomorphic sources include arsenical-
containing fungicides, pesticides, and herbi-
cides. For example, in Novi, Michigan, 95
acres of land proposed for development are
contaminated with arsenic from insecticides
dating from when the land was used for
orchards. In Michigan, chronic effects of
arsenic include neurological effects similar to
those of multiple sclerosis (Detroit Free Press
1997). It is likely that over a period of
decades some of these effects will progress to
various cancers (Detroit Free Press 1999).
Thus, study of the mechanisms of arsenic
detoxiﬁcation in humans and other organisms
is of considerable importance.
Convergent Evolution of
Arsenate Reductases
Pathways for arsenic detoxiﬁcation exist in all
organisms examined, including bacteria and
yeast (Bhattacharjee et al. 1999) (Figure 1).
An initial step is biotransformation of arsenate
[As(V)] to arsenite [As(III)] (Figure 1).
Although As(V) can be reduced to As(III)
nonenzymatically, this process is too slow to
be physiologically signiﬁcant, and organisms
use enzymes that catalyze As(V) reduction
(Bhattacharjee et al. 1999). These thiol-linked
reductases are required to confer resistance to
As(V) in both prokaryotes (Gladysheva et al.
1994; Ji et al. 1994) and eukaryotes
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The ubiquity of arsenic in the environment has led to the evolution of enzymes for arsenic detoxiﬁ-
cation. An initial step in arsenic metabolism is the enzymatic reduction of arsenate [As(V)] to arsen-
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convergent evolution. The properties of two of these are described here. The ﬁrst is the prokaryotic
ArsC arsenate reductase of Escherichia coli. The second, Acr2p of Saccharomyces cerevisiae, is the
only identiﬁed eukaryotic arsenate reductase. Although unrelated to each other, both enzymes receive
their reducing equivalents from glutaredoxin and reduced glutathione. The structure of the bacterial
ArsC has been solved at 1.65 Å. As predicted from its biochemical properties, ArsC structures with
covalent enzyme–arsenic intermediates that include either As(V) or As(III) were observed. The yeast
Acr2p has an active site motif HC(X)5R that is conserved in protein phosphotyrosine phosphatases
and rhodanases, suggesting that these three groups of enzymes may have evolved from an ancestral
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Figure 1. Pathways of arsenic detoxiﬁcation in prokaryotes and eukaryotes. E. coli, a typical prokaryote,
accumulates As(V) by phosphate transport systems such as the Pst ABC ATPase. As(V) is reduced to As(III)
by ArsC, a Grx–GSH-linked enzyme. The resulting As(III) is pumped out of the cells by the ArsA/ArsB
ATPase. The eukaryote S. cerevisiae uses a similar cycle of As(V) uptake, reduction, and extrusion from the
cytosol, but the proteins that catalyze these reactions are the products of independent evolution from the
bacteria. Phosphate transporters such as Pho84p accumulate As(V). Acr2p, a Grx–GSH-linked enzyme,
reduces As(V) to As(III). As(III) can be extruded from the cells by the Acr3p carrier. Alternatively, As(III) can
be conjugated with GSH to form As(GS)3. The Ycf1p ABC ATPase removes As(III) from the cytosol by pump-
ing As(GS)3 into the vacuole.746 VOLUME 110 | SUPPLEMENT 5 | OCTOBER 2002 • Environmental Health Perspectives
(Bobrowicz et al. 1997; Mukhopadhyay and
Rosen 1998). These enzymes arose indepen-
dently at least three times by convergent evo-
lution (Figure 2). One family includes the
Staphylococcus aureus plasmid pI258–encoded
arsC gene product (Ji et al. 1994). This ArsC
enzyme is homologous to low molecular
weight protein phosphotyrosine phosphatases
(lmwPTPases) (Bennett et al. 2001). A second
family includes the Escherichia coli plasmid
R773 ArsC arsenate reductase (Rosen 1999).
The third family includes the only known
eukaryotic arsenate reductase, Acr2p from
Saccharomyces cerevisiae (Bobrowicz et al.

























Figure 2. Three families of arsenate reductases.
Reductases involved in As(V) detoxification have
apparently evolved independently at least three
times. One family is typified by the E. coli plasmid
R773 ArsC that uses Grx and GSH as reductants. A
second family represented by the S. aureus plasmid
pI258 ArsC uses thioredoxin (Trx) as a reductant
and is related to a family of lmwPTPases. Acr2p is
the only eukaryotic arsenate reductase so far iden-
tiﬁed. It belongs to the superfamily of PTPases that




















ArsC-Cys12-SH + As = O
ArsC-Cys12-S-As+-OH
+ GrxS-SG
Figure 3. The reaction mechanism of the R773 ArsC.
In the ﬁrst step, an oxyanion [As(V), phosphate, or
sulfate] is bound noncovalently to the enzyme. If
the oxyanion is As(V), a covalent thiarsahydroxy
intermediate forms with the thiolate of Cys12, as
has been seen in the crystal structure of the As(V)
complex. In the third step, a glutathionylated inter-
mediate is formed that is then reduced to novel
ArsC–S–As+–O intermediate observed in the
enzyme–As(III) crystal structure. In the final step,
this enzyme–As(III) complex dissociates to release
free As(III).
Figure 4. Crystal structure of the R773 ArsC at 1.65 Å. Two views are shown identifying secondary struc-
tural elements (left) or space ﬁlling (right). The active site includes the catalytic residue Cys12 and argi-
nine residues Arg60 and Arg94, which are shown in stick form. The catalytic residue Cys12 is held in a
rigid loop formed by two type I beta turns that bracket the cysteine (left). Arg94 forms a portion of the
anion-binding site, and Arg60 stabilizes the covalent thiarsahydroxy intermediate.
Acr2p            MVSFITSRQLK-----GLIENQRKDFQVVDLRR-EDFARDHITNAWHVPVTAQ
Yg4ep     MDSYSITNVKYLDPTELHRWMQEGHTTTLREPFQVVDVRGS-DYMGGHIKDGWHYAYSRL
Cdc25a    TVAGKHQDLKYISPETMASVLNGKFA-NLIKEFYIIDCRYPYEYEGGHIKGAVNLHMEEE
76    82
Acr2p     ITEKQ-LNQLIKGLSDTFSSSQ-FVKVIFHCTGSKNRGPKVAAKFETYLQEEDITSK---
Yg4ep     KQDPEYLRELKHRLLEKQADGRGALNVIFHCMLSQQRGPSAAMLLLRSLDTAEL-SR---
Cdc25a    VEDF----LLKKPIVPTD---GKRVIIVFHCEFSSERGPRMCRYVRERDRLGNEYPKLHY
Acr2p     FESCILVGGFYAWETHC--RESNLKLIVSG
Yg4ep     CRLWVLRGGFSRWQSVYGDDESVTAGYLPDLWR
Cdc25a    ELYVLKGGYKEFFMKCQSYCEPPSYRPMHHEDF
A
B
Figure 5. Active site of the yeast Acr2p arsenate reductase. (A) Alignment of Acr2p with Yg4ep, an S. cere-
visiae homolog, and the human Cdc25a. The consensus active site HC(X)5R motif is identiﬁed. (B) Structure
of the human Cdc25a. The active site Cys430 is identiﬁed, as is His429 that charge-pairs with Cys430, and
Arg436, which forms part of the anion-binding loop. Acr2p is predicted to have a similar active site.Environmental Health Perspectives • VOLUME 110 | SUPPLEMENT 5 | OCTOBER 2002 747
1997; Mukhopadhyay and Rosen 1998).
Acr2p is homologous to the Cdc25a cell-cycle
protein tyrosine phosphatase (PTPase)
(Fauman et al. 1998) and to rhodanase, a
thiosulfate sulfurtransferase (Hofmann et al.
1998). It is interesting that the substrates of all
three types of enzymes, arsenate reductases,
phosphatases and sulfurtransferases, are
anions. This evolutionary relatedness suggests
that the common ancestor had an oxyanion-
binding site. We have studied ArsC from
E. coli resistance plasmid R773 and the yeast
Acr2p, and the properties of those two
enzymes are described here in more detail.
ArsC: A Prokaryotic
Arsenate Reductase
The R773 ArsC puriﬁed from E. coli requires
reduced glutathione (GSH) and the small
thiol transfer protein glutaredoxin (Grx) for
arsenate reductase activity (Gladysheva et al.
1994). ArsC has a single catalytic cysteine
residue, Cys12 (Liu et al. 1995), that forms a
covalent thiolate–As(V) intermediate (Martin
et al. 2001). Grx is required to reduce the
enzyme-bound ES–As(V) intermediate to an
ES–As(III) intermediate (Gladysheva et al.
1994; Shi et al. 1999). Members of the Grx
family have two ways in which they can par-
ticipate in thiol reduction reactions. First, they
can catalyze reduction of intramolecular disul-
ﬁde bonds (Bushweller et al. 1992). Because
ArsC has only a single required cysteine
residue, this seemed an unlikely mode of
action of Grx. Second, Grx can participate in
reduction of mixed disulﬁdes between protein
thiols and glutathione. The two modes can be
differentiated by the use of appropriate Grx
mutants. There are three glutaredoxins in E.
coli, Grx1, Grx2, and Grx3 (Åslund et al.
1994), each of which can function in ArsC
catalysis (Shi et al. 1999). Each has the
consensus sequence Cys–Pro–Tyr–Cys.
Mutants lacking the N-terminal cysteine are
unable to participate in either mode of reduc-
tion. In contrast the C-terminal cysteine
mutants function in reduction of mixed pro-
tein-glutathione disulﬁdes but not reduction
of intramolecular protein disulfide bonds
(Bushweller et al. 1992). N-terminal cysteine
mutants of Grx could not participate in ArsC-
catalyzed As(V) reduction (Shi et al. 1999).
On the other hand, Grx mutants lacking the
C-terminal cysteine still supported ArsC activ-
ity. These results demonstrate that ArsC does
not form an intramolecular disulfide during
the catalytic cycle and are consistent with the
existence of the mixed disulﬁde intermediate
ArsC–S–SG. However, as described below,
crystallographic data suggest that the interme-
diate could be a novel thiarsahydroxy
ArsC–S–As(OH)–SG complex. An ArsC
reaction scheme with the As(V) and As(III)
intermediates is shown in Figure 3.
We have recently reported the X-ray
crystal structures of ArsC at 1.65 Å (Martin
et al. 2001). The active site can be seen to
consist of the catalytic residue Cys12 and sev-
eral arginine residues, including Arg60 and
Arg94 (Figure 4). In addition to the native
structure, structures of ArsC in complex with
As(V) or As(III) were obtained. One structure
is that of the covalent Cys12–S–As(V)
adduct, which has a tetrahedral geometry
with a sulfur–arsenic distance of 2.18 Å. The




Although it is likely that enzymes that
catalyze As(V) reduction are ubiquitous, the
only eukaryotic arsenate reductase identified
is the 130-residue Acr2p protein from S. cere-
visiae (Bobrowicz et al. 1997; Mukhopadhyay
and Rosen 1998; Mukhopadhyay et al.
2000). The ACR2 gene is required for
As(V) resistance (Bobrowicz et al. 1997;
Mukhopadhyay and Rosen 1998). Acr2p is
apparently unrelated to bacterial arsenate
reductases. On the other hand, it is a member
of the superfamily of PTPases such as the
human cell-cycle dual-specific phosphatase
Cdc25a (Figure 5A). Members of this family
have a consensus-active site HC(X)5R motif
(Denu and Dixon 1995; Fauman et al. 1998)
(Figure 5B). The consensus C76(X)5R82 motif
of Acr2p is likely to be part of the active site
as well: either Cys76 or Arg82 mutations
result in loss of As(V) resistance in vivo and
As(V) reduction in vitro (Mukhopadhyay and
Rosen 2001). These results suggest that
Cys76 is the equivalent of Cys12 in ArsC and
may form As(V) and As(III) intermediates. In
support of this hypothesis, in vitro Acr2p
exhibits the same Grx and GSH requirement
as ArsC. All Grx proteins examined supported
Acr2p activity, including a S. cerevisiae Grx
and all three E. coli Grx proteins. Just as in the
case of ArsC, the Grx C-terminal cysteine
mutants functioned in As(V) reduction, indi-
cating that Acr2p could have a catalytic cycle
with an Acr2p–S–As(III)–SG intermediate
(Mukhopadhyay et al. 2000).
Where are the mammalian arsenate
reductases? Reductase activity has recently
been reported in human liver (Radabaugh and
Aposhian 2000), but it is not known whether
the enzyme that catalyzes this activity is related
to Acr2p or either of the bacterial enzymes.
The S. aureus plasmid pI258 ArsC and the
yeast Acr2p enzymes are both homologues of
protein phosphotyrosine phosphatases
(although to different families of phosphatase)
(Bennett et al. 2001; Fauman et al. 1998).
Acr2p is also homologous to rhodanases,
which are thiosulfate sulfurtransferases
(Hofmann et al. 1998). We suggest that all
arsenate reductases, whether eukaryotic or
prokaryotic, share a common evolutionary
lineage with phosphatases. Analysis of the
phosphatase-like proteins identified in
eukaryotic genomes may reveal the identity of
mammalian arsenate reductase.
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